Present study results also correspond with the previously reported role of FLG2 mutations in early stages of carcinogenesis as they have been found in precancerous lesions but not in gastric adenocarcinoma or peritoneal gastric cancer metastases [49]. This evidence concerns the gene FLG2 and gastric adenocarcinoma.